You are here

A NOVEL ANTIFUNGAL COMPOUND FROM CAYENNE PEPPER

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 1R43AI047617-01A1
Amount: $99,582.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
12635 E MONTVIEW BLVD
AURORA, CO 80010
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CLAUDE SELITRENNIKOFF
 () -
Business Contact
Phone: (720) 859-4190
Email: CLAUDE.SELITRENNIKOFF@UCHSC.EDU
Research Institution
N/A
Abstract

DESCRIPTION (Adapted from the application): Deep-seated mycoses are being
increasingly observed in immunocompromised patients and in patients receiving
aggressive cancer chemotherapy. The use of available drugs for the treatment of
these infections is limited by toxicity and the emergence of resistant fungal
species. The impact of fungal infections in the clinical management of
inimunocompromised patients underscores the clear need for new antifungals.

Historically, microorganisms and plants have been rich sources of drugs for the
treatment of human disease. We have identified a novel, broadly-active
antifungal compound from the dried fruit of Capsicum spp. (cayenne pepper).
CAY-1, the active agent, was purified to homogeneity and, based on chemical
analysis, is a novel saponin with a molecular mass of 1243 Da. In this Phase I
proposal, we plan to extend our preliminary work and characterize more fully
CAY-1's potential as an antifungal therapeutic. We will accomplish this in
three specific aims:

A. Aim One: Purify 500 mg of CAY-1 for the work described in Aims Two through
Four

C. Aim Two: Characterize the antifungal activity of CAY-1.

D. Aim Three. Determine the in vitro toxicity of CAY-1 and the in vivo efficacy
of CAY-1 against Candida albicans
PROPOSED COMMERCIAL APPLICATION:
The research outlined in this Phase I SBIR proposal will lead to the evaluation of a novel
antifungal compound. We estimate that the market potential for a novel and safe antifungal
drug to be greater than $200,000,000 per year.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government